Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2003-03-11
2009-06-02
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S143100, C424S185100, C435S007100, C435S070210, C435S810000, C530S327000, C530S387100, C530S388220, C530S389100
Reexamination Certificate
active
07541027
ABSTRACT:
The present invention relates to the use of the epitope which comprises the tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor, KDR/Flk-1, as a marker in the measurement of a change in the activation state of the KDR/Flk-1 receptor and to probes, such as antibodies, which recognize said epitope. The invention also relates to the use of KDR/Flk-1 epitope Y1214 as a marker in the detection of and/or measurement of the level of the KDR/Flk-1 receptor and to assays which utilize the use of the Y1214 epitope and to compounds derived from said assays.
REFERENCES:
patent: 5766860 (1998-06-01), Terman et al.
patent: 5840301 (1998-11-01), Rockwell et al.
patent: 6204011 (2001-03-01), Kendall et al.
patent: WO 0229090 (2002-04-01), None
Takahashi et al, EMBO J 20(11): 2768-2778, Jun. 2001.
Stryer et al, in Biochemistry, Third edition, W H Freeman Company, New York, pp. 31-33, 1998.
Kuby et al, Immunology, Second edition, pp. 85-96, 1994.
Zhu et al, Investigational New Drugs 17: 195-212, 1999.
Harlow et al, in Antibodies a Laboratory Manual, 1988, Cold Spring harbor laboratory publication, Cold Spring Harbor, NY, pp. 139-153.
Wallace et al, in Methods in Enzymology 152: 432-439, 1987.
Harlow et al, in Antibodies a Laboratory Manual, 1988, Cold Spring harbor laboratory publication, Cold Spring Harbor, NY, pp. 626-629.
Clauss M (2000) Molecular biology of the VEGF and the VEGF receptor family Semin Thromb Hemost. 26(5)561-569.
Cullinan-Bove K et al. (1993) Vascular endothelial growth factorvascular permeability factor expression in the rat uterus rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth Endocrinology 133 829-837.
Cunningham SA et al. (1997) Interactions of FLT-1 and KDR with phospholipase C gamma. Indentification of the phosphotyrosine binding sites Biochem. Biophys. Res. Comm. Biochem. Biophys. Res. Comm. 240635-639.
Dougher M et al. (1999) Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization Oncogene 18(8)1619-1627.
Fan TP et al. (1995) Controlling the vasculature angiogenesis, anti-angiogenesis and vascular targeting of gene therapy Trends Pharmacol Sci. 16(2)57-66.
Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease Nature Medicine. 1(1)27-31.
Karkkainen MJ et al. (2000) Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis Oncogene 195598-5605.
Kendall RL et al. (1999) Vascular Endothelial Growth Factor Receptor KDR Tyrosine Kinase Activity Is Increased by Autophosphorylation of Two Activation Loop Tyrosine Residues J Biol Chem 274(10)6453-6460.
McMahon G (2002) VEGF receptor signaling in tumor angiogenesis Oncologist. 5 Suppl 13-10.
Ratcliffe KE et al. (2002) Sck is expressed in endothelial cells and participates in vascular endothelial growth factor-induced signaling Oncogene 21(41)6307-6316.
Senger DR et al. (1993) Vascular Permeability Factor (VPF, VEGF) in Tumor Biology Cancer Met Reviews 12303-324.
Terman BI et al. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 61677-1683.
Terman BI et al. (1992) Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor Biochem Biophys Res Commun. 187(3)1579-1586.
Warner AJ et al. (2000) The Shc-related adaptor protein, Sck, forms a complex with the vascular-endothelial-growth-factor receptor KDR in transfected cells Biochem J. 347(Pt2)501-509.
Zeng H (2001) Tyrosine Residues 951 and 1059 of Vascular Endothelial Growth Factor Receptor-2 (KDR) Are Essential for Vascular Permeability Factor Vascular Endothelial Growth Factor-induced Endothelium Migration and Proliferation, Respectively J. Biol. Chem. 276(35)32714-32719.
Wood et al. (2000) “PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration” Cancer Res. 60(8):2178-2189.
Igarashi et al. (1998) “Tyrosine 1213 of Flt-1 Is a Major Binding Site of Nck and SHP-2” Biochemical and Biophysical Research Communications 246(1): 95-99 (p. 98, right-hand col., last paragraph-p.99; figs. 2-4).
Carroll et al. (1999) “KDR activation in astrocytic neoplasms” Cancer 86(7): 1335-1341 (Abstract).
Menrad et al. (1997) “Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II” Hybridoma 16(5): 465-471 (Abstract, p. 469).
Zhu et al. (1999) “Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti- kinase insert domain-containing receptor antibody” Cancer Letters 136(2): 203-213 (Abstract, p. 210, left-hand col., last paragraph—right-hand col.).
Rockwell et al. (1995) “In-vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody” Mol. Cell. Diff. 3(1): 91-109 (p. 102, paragraphs 2,3, abstract).
Meyer et al. (2002) “The Presence of a Single Tyrosine Residue at the Carboxyl Domain of Vascular Endothelial Growth Factor Receptor-2/FLK-1 Regulates Its Autophosphorylation and Activation of Signaling Molecules” J. Biol. Chem., 277(30): 27081-27087 (Abstract, figs. 1, 4-6).
Wood et al., Cancer Research, vol. 60, No. 8, Apr. 15, 2000, pp. 2178-2189, XP000971163, ISSN: 0008-5472, abstract.
Igarashi Katsuhide et al., Biochemical and Biophysical Research Communications, vol. 246, No. 1, May 8, 1998, pp. 95-99, XP002251094, ISSN: 0006-291X, p. 98, right-hand col., last paragraph-p. 99; figs. 2-4.
Carrol Rona et al., Cancer, vol. 86, No. 7, Oct. 1, 1999, pp. 1335-1341, XP002251095, ISSN: 0008-543X, abstract.
Takahashi et al,. The Embo Journal, England, vol. 20, No. 11, Jun. 1, 2001, pp. 2768-2778, XP002251096, ISSN: 0261-4189, cited in application, abstract, fig. 1, pp. 2769, left-hand col., para. 1.
Menrad et al., Hybridoma, vol. 16, No. 5, Oct. 1, 1997, pp. 465-471, XP002052460, ISSN: 0272-457X, abstract, p. 469.
Zhu et al., Cancer Letters, vol. 136 No. 2, Mar. 1, 1999, p[p. 203-213, XP002251097, ISSN: 0304-3835, abstract, p. 210, left-hand col., last paragraph—right-hand col.
Rockwell et al., Mollecular and Cellular Differentiation, vol. 3, No. 1, 1995, pp. 91-109, XP002052455, ISSN: 1065-3074, p. 102, paragraphs 2,3, abstract.
Meyer et al., Journal of Biological Chemistry, vol. 277, No. 30, May 22, 2002, pp. 27081-27087, XP002251098, Jul. 28, 2002, ISSN: 0021-9258, abstract, figs. 1, 4-6.
Astrazeneca AB
Huynh Phuong
Morgan & Lewis & Bockius, LLP
LandOfFree
Use of an epitope of vascular endothelial growth factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of an epitope of vascular endothelial growth factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of an epitope of vascular endothelial growth factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4146554